Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TALARIS THERAPEUTICS, INC.

(TALS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
12.15(c) 12.86(c) 13.27(c) 13.5(c) 14.13(c) Last
20 182 30 028 17 681 35 884 33 867 Volume
-5.96% +5.84% +3.19% +1.73% +4.67% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -44,6 M - -
Net Debt 2021 85,1 M - -
P/E ratio 2021 -10,0x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -63,0 M - -
Net Debt 2022 154 M - -
P/E ratio 2022 -10,4x
Yield 2022 -
Capitalization 584 M 584 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 91
Free-Float 86,6%
More Financials
Company
Talaris Therapeutics, Inc. is a late-clinical stage, cell therapy company developing therapies. The Company is principally focused on developing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The Company's lead product candidate, FCR001, which is central to its facilitated Allo-HSCT therapy, is an allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor.... 
More about the company
All news about TALARIS THERAPEUTICS, INC.
09/02TALARIS THERAPEUTICS : to Participate at Two Upcoming Virtual Investor Conferenc..
AQ
08/12TALARIS THERAPEUTICS : Management's Discussion and Analysis of Financial Conditi..
AQ
08/12TALARIS THERAPEUTICS : On track to provide FREEDOM-1 initial clinical update, in..
PU
08/12TALARIS THERAPEUTICS, INC. : Results of Operations and Financial Condition, Fina..
AQ
08/12TALARIS THERAPEUTICS : Earnings Flash (TALS) TALARIS THERAPEUTICS Reports Q2 Los..
MT
08/12Talaris Therapeutics Announces Second Quarter 2021 Financial Results and Prov..
GL
08/12Talaris Therapeutics, Inc. Announces Unaudited Earnings Results for the Secon..
CI
06/21TALARIS THERAPEUTICS, INC.(NASDAQGM : TALS) added to S&P TMI Index
CI
06/15TALARIS THERAPEUTICS : Reports Wider Loss Per Share in Q1
MT
06/14TALARIS THERAPEUTICS : Management's Discussion and Analysis of Financial Conditi..
AQ
06/14TALARIS THERAPEUTICS : Announces First Quarter 2021 Financial Results and Provid..
PU
06/14TALARIS THERAPEUTICS, INC. : Results of Operations and Financial Condition, Fina..
AQ
06/14TALARIS THERAPEUTICS : Earnings Flash (TALS) TALARIS THERAPEUTICS Posts Q1 Loss ..
MT
06/14Talaris Therapeutics Announces First Quarter 2021 Financial Results and Provi..
GL
06/14Talaris Therapeutics, Inc. Announces Earnings Results for the First Quarter E..
CI
More news
News in other languages on TALARIS THERAPEUTICS, INC.

- No features available -

More news
Analyst Recommendations on TALARIS THERAPEUTICS, INC.
More recommendations
Chart TALARIS THERAPEUTICS, INC.
Duration : Period :
Talaris Therapeutics, Inc. Technical Analysis Chart | TALS | US87410C1045 | MarketScreener
Technical analysis trends TALARIS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 14,13 $
Average target price 29,25 $
Spread / Average Target 107%
EPS Revisions
Managers and Directors
Scott Requadt President, Chief Executive Officer & Director
Mary Kay Fenton Chief Financial Officer
Francois Nader Chairman
Suzanne T. Ildstad Chief Scientific Officer & Director
Nancy Krieger-Eddy Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
TALARIS THERAPEUTICS, INC.0.00%584
MODERNA, INC.311.65%173 588
LONZA GROUP AG32.35%60 074
IQVIA HOLDINGS INC.43.07%49 116
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-10.81%28 420